135 related articles for article (PubMed ID: 14735180)
1. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
Gronlund B; Hansen HH; Høgdall C; Høgdall EV; Engelholm SA
Br J Cancer; 2004 Jan; 90(2):377-82. PubMed ID: 14735180
[TBL] [Abstract][Full Text] [Related]
2. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer.
Tsuda H; Hashiguchi Y; Nakata S; Deguchi M; Negoro S; Ishiko O; Yamamoto K
Int J Gynecol Cancer; 2002; 12(5):435-7. PubMed ID: 12366658
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
4. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?
Gronlund B; Høgdall C; Christensen IJ; Engelholm SA; Hansen HH
Gynecol Oncol; 2004 Aug; 94(2):409-15. PubMed ID: 15297181
[TBL] [Abstract][Full Text] [Related]
5. CA125 Nadir values as a prognostic factor in epithelial ovarian cancer.
Altundag K; Altundag O; Morandi P; Gunduz M
J Clin Oncol; 2005 Apr; 23(10):2435-6; author reply 2436. PubMed ID: 15800343
[No Abstract] [Full Text] [Related]
6. CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation.
Colloca G; Venturino A; Addamo G; Coccorullo Z; Ratti R; Caltabiano G; Guarneri D
Jpn J Clin Oncol; 2013 Dec; 43(12):1203-9. PubMed ID: 24038194
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
Gronlund B; Høgdall C; Hilden J; Engelholm SA; Høgdall EV; Hansen HH
J Clin Oncol; 2004 Oct; 22(20):4051-8. PubMed ID: 15364966
[TBL] [Abstract][Full Text] [Related]
9. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Rustin GJ; van der Burg ME; Griffin CL; Guthrie D; Lamont A; Jayson GC; Kristensen G; Mediola C; Coens C; Qian W; Parmar MK; Swart AM; ;
Lancet; 2010 Oct; 376(9747):1155-63. PubMed ID: 20888993
[TBL] [Abstract][Full Text] [Related]
10. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Cancer; 2002 Apr; 94(7):1961-7. PubMed ID: 11932898
[TBL] [Abstract][Full Text] [Related]
11. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
[TBL] [Abstract][Full Text] [Related]
12. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
14. Has serum CA 125 assay at the time of relapse a prognostic relevance for patients with recurrent ovarian carcinoma after primary cytoreduction and platinum- and paclitaxel-based chemotherapy?
Gadducci A; Notarnicola M; Menichetti A; Lanfredini N; Fanucchi A; Cosio S
Eur J Gynaecol Oncol; 2016; 37(2):182-8. PubMed ID: 27172742
[TBL] [Abstract][Full Text] [Related]
15. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
Rustin GJ; Nelstrop AE; Crawford M; Ledermann J; Lambert HE; Coleman R; Johnson J; Evans H; Brown S; Oster W
J Clin Oncol; 1997 Jan; 15(1):172-6. PubMed ID: 8996139
[TBL] [Abstract][Full Text] [Related]
17. 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
Ishikawa H; Nakanishi T; Nawa A; Suzuki Y; Kuzuya K
Int J Clin Oncol; 2001 Jun; 6(3):128-31. PubMed ID: 11706781
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis.
Kim JH; Cho HW; Park EY; Han KH; Kim ET; Lee JK; Park SY; Armbrust R; Fotopoulou C; Lim MC
Int J Gynecol Cancer; 2023 Dec; 33(12):1913-1920. PubMed ID: 37949486
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
20. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Hoskins P; Eisenhauer E; Vergote I; Dubuc-Lissoir J; Fisher B; Grimshaw R; Oza A; Plante M; Stuart G; Vermorken J
J Clin Oncol; 2000 Dec; 18(24):4038-44. PubMed ID: 11118464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
